SCHEMBL2125283

SCHEMBL2125283

CCONS(=O)(=O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.50
MEN1 O00255 1/20 0.50
MAPT P10636 1/20 0.50
PSIP1 O75475 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 4/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
MMP1 P03956 1/20 0.47
MMP2 P08253 1/20 0.47
MMP9 P14780 1/20 0.47
MMP8 P22894 1/20 0.47
MMP13 P45452 1/20 0.47
TSHR P16473 2/20 0.46
KDM4E B2RXH2 4/20 0.46
MAPK1 P28482 1/20 0.46
LMNA P02545 3/20 0.46
KEAP1 Q14145 2/20 0.46
PKM P14618 1/20 0.46
HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6831186 0.82 ALDH1A1 (0.58) KMT2AMEN1MAPTSMN1; SMN2ALDH1A1
SCHEMBL27529410 0.82 ALDH1A1 (0.60) KMT2AMEN1MAPTPSIP1SMN1; SMN2
SCHEMBL28079516 0.81 CA1 (0.56) SMN1; SMN2ALDH1A1CA1CA2MMP1
SCHEMBL27990218 0.80 ALDH1A1 (0.55) KMT2AMEN1MAPTPSIP1SMN1; SMN2
SCHEMBL11086966 0.79 MAPK1 (0.58) KMT2AMAPTSMN1; SMN2ALDH1A1CA1
SCHEMBL8761040 0.79 ALDH1A1 (0.54) SMN1; SMN2ALDH1A1TSHRKDM4EMAPK1
SCHEMBL28326525 0.79 L3MBTL1 (0.60) KMT2AMEN1SMN1; SMN2ALDH1A1MAPK1
SCHEMBL28313674 0.79 KEAP1 (0.49) KMT2AMAPTSMN1; SMN2ALDH1A1TSHR
SCHEMBL10837819 0.78 KMT2A (0.64) KMT2ASMN1; SMN2ALDH1A1CA1CA2
SCHEMBL10407475 0.77 ALDH1A1 (0.49) KMT2AMEN1SMN1; SMN2ALDH1A1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110642791-A Sulfonylurea compound, preparation method thereof and application thereof in preparing herbicide 南开大学 2020-01-03 CN claimed
CN-101111240-B Isolation of n-butylbenzenesulfonamide, synthesis of benzenesulfonamide derivatives, and use of n-butylbenzenesulfonamide and benzenesulfonamide derivatives for the treatment of benign prostate hyperp LOHMANN THERAPIE SYST LTS 2011-09-21 CN claimed
CN-114585605-B Pharmaceutical compounds 圣提内尔肿瘤学有限公司 2025-02-25 CN disclosed
CN-114846000-B 2-Amino-N- (amino-oxo-aryl-lambda 6-sulfinyl) acetamide compounds and therapeutic uses thereof 牛津药物设计有限公司 2025-01-03 CN disclosed
US-20240400536-A1 IDEBENONE DERIVATIVES AND THEIR USE IN TREATING PLANTS MITORX THERAPEUTICS LTD (GB) 2024-12-05 US disclosed
CN-110396085-B Combination therapy 爱尔康公司 2024-11-15 CN disclosed
CN-113891891-B Modulators of AMPA receptor signaling 戒毒及精神健康中心 2024-10-11 CN disclosed
CN-113950476-B Substituted 4- [5- (benzofuran-2-yl) -1,2, 4-oxadiazol-3-yl ] benzoic acid compounds for the treatment of neuropathic pain 伦敦皇家学院 2024-08-16 CN disclosed
CN-118234716-A Idebenone derivatives and their use in the treatment of plants 米托克斯治疗有限公司 2024-06-21 CN disclosed
CN-117813121-A Biphosphine compounds and complexes 癌症研究技术有限公司 2024-04-02 CN disclosed
CN-117642395-A Azetidinyl pyrimidines and their use 爱瑞制药公司 2024-03-01 CN disclosed
WO-2003068226-A1 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS PHARMAGENE LABORATORIES LIMITED (GB) 2003-08-21 WO disclosed
WO-2003068227-A1 5-HT2B RECEPTOR ANTAGONISTS PHARMAGENE LABORATORIES LIMITED (GB) 2003-08-21 WO disclosed
EP-1330442-A1 PHTHALAZINONE DERIVATIVES Kudos Pharmaceuticals Limited (GB) 2003-07-30 EP disclosed
EP-1305026-A2 BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS Novuspharma S.p.A. (IT) 2003-05-02 EP disclosed
WO-2003024949-A1 DNA-PK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2003-03-27 WO disclosed
WO-2003015790-A1 THIOPYRANE-4-ONES AS DNA PROTEIN KINASE INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2003-02-27 WO disclosed
WO-2002090334-A1 ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS KUDOS PHARMACEUTICALS LIMITED (GB) 2002-11-14 WO disclosed
WO-2002036576-A1 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2002-05-10 WO disclosed
WO-2001093841-A2 BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS NOVUSPHARMA S.P.A. (IT) 2001-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400536-A1 IDEBENONE DERIVATIVES AND THEIR USE IN TREATING PLANTS AIFM1, TUFM, SQOR KMT2A 4827/4885MEN1 4628/4885MAPT 2216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.